MedPath

Molibresib

Generic Name
Molibresib
Drug Type
Small Molecule
Chemical Formula
C22H22ClN5O2
CAS Number
1260907-17-2
Unique Ingredient Identifier
5QIO6SRZ2R
Background

Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).

Clinical Trials
Related News

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Phase 1
Withdrawn
Conditions
Unresectable NUT Carcinoma
Metastatic NUT Carcinoma
Interventions
First Posted Date
2019-10-04
Last Posted Date
2020-09-28
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT04116359

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Phase 1
Withdrawn
Conditions
Advanced Lymphoma
Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma
Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma
Refractory Malignant Solid Neoplasm
Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Refractory Lymphoma
Refractory T-Cell Non-Hodgkin Lymphoma
Stage II Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Interventions
First Posted Date
2019-04-24
Last Posted Date
2020-09-28
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT03925428

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma

Conditions
Solid Tumours
First Posted Date
2018-10-10
Last Posted Date
2020-04-13
Lead Sponsor
GlaxoSmithKline
Registration Number
NCT03702036

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1
Terminated
Conditions
Solid Tumours
Interventions
First Posted Date
2017-05-11
Last Posted Date
2022-08-10
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
73
Registration Number
NCT03150056
Locations
🇬🇧

GSK Investigational Site, Glasgow, United Kingdom

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase 1
Terminated
Conditions
Neoplasms
Interventions
Drug: Placebo
First Posted Date
2016-11-16
Last Posted Date
2024-08-29
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
124
Registration Number
NCT02964507
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

Phase 2
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2013-09-17
Last Posted Date
2024-10-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
111
Registration Number
NCT01943851
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

Phase 1
Completed
Conditions
Carcinoma, Midline
Interventions
First Posted Date
2012-04-30
Last Posted Date
2020-03-16
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
196
Registration Number
NCT01587703
Locations
🇬🇧

GSK Investigational Site, Newcastle upon Tyne, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy